![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, April 19, 2021 1:50:53 PM
In the U.S., it's going to be an uphill climb to unseat FDA/Fauci's darling Remdesivir for standard of care. Remdesivir failed multiple trials and even the WHO warned against it's use, but that still has not stopped it here in the U.S. The NIH trial pairing Aviptadil with/against Remdesivir will hopefully solve the Remdesivir issue once and for all, but it's going to take awhile. I expect that RLF will get revenue from the EU before the NIH trial is finished.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM